This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Japan Medical Association Center for Clinical Trials | |
|---|---|
| Name | Japan Medical Association Center for Clinical Trials |
| Native name | 日本医師会臨床試験センター |
| Founded | 2001 |
| Headquarters | Tokyo |
| Parent organization | Japan Medical Association |
Japan Medical Association Center for Clinical Trials
The Japan Medical Association Center for Clinical Trials is a Japanese clinical research organization based in Tokyo that supports clinical trials, ethical review, and investigator training across Japan. It operates within the institutional network of the Japan Medical Association and interfaces with regulatory bodies, academic hospitals, and pharmaceutical and device industries to promote Good Clinical Practice and evidence generation. The center is involved with national initiatives, multicenter studies, capacity building, and dissemination of trial results in domestic and international forums.
Established in 2001 as an initiative of the Japan Medical Association and in response to regulatory changes influenced by the Pharmaceutical Affairs Law (Japan), the center grew amid debates involving the Ministry of Health, Labour and Welfare (Japan), the Health, Labour and Welfare Bureau, and stakeholders such as the Japanese Society of Internal Medicine and the Japanese Surgical Society. Early work focused on implementing standards comparable to those of the United States Food and Drug Administration, the European Medicines Agency, and guidance from the World Health Organization. The center expanded after high-profile events, including revisions to clinical trial frameworks following incidents scrutinized by the Diet of Japan and coverage in outlets like the Yomiuri Shimbun and the Asahi Shimbun. Its evolution paralleled institutional developments at the National Center for Global Health and Medicine, the Japan Agency for Medical Research and Development, and university hospitals such as University of Tokyo Hospital and Kyoto University Hospital.
Governance is provided through oversight by the Japan Medical Association council and advisory input from committees including representatives from the Japanese Association of Medical Sciences, the Japan Pharmaceutical Manufacturers Association, and the Japan Clinical Oncology Group. Executive leadership liaises with regulatory entities such as the Pharmaceuticals and Medical Devices Agency and academic partners like Osaka University Hospital and Tohoku University Hospital. Institutional review boards and ethics committees coordinate with professional societies including the Japanese Circulation Society and the Japan Diabetes Society. The center maintains policies aligned with international norms set by bodies like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and engages legal counsel familiar with the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.
Services include protocol development, data management, biostatistics, monitoring, and training for investigators from institutions such as St. Luke's International Hospital, Kobe University Hospital, and Hokkaido University Hospital. The center runs Good Clinical Practice training recognized by professional organizations like the Japanese Society of Nephrology and the Japanese Respiratory Society and offers support for investigator-initiated trials involving collaborators such as the Japanese Association of Cardiovascular Intervention and Therapeutics. It provides ethical review services paralleling standards used by the Council for International Organizations of Medical Sciences and conducts workshops with stakeholders including the Japan Association of Medical Sciences and the Japan Society of Clinical Oncology.
Facilities include centralized data centers, electronic data capture systems, and clinical trial units that partner with tertiary centers like Saitama Medical University Hospital and specialty institutes such as the National Cancer Center Hospital. The center's monitoring teams coordinate site management across networks that include community hospitals and teaching hospitals such as Nagasaki University Hospital and Fukuoka University Hospital. Laboratory collaborations include affiliations with reference laboratories used by the National Institute of Infectious Diseases (Japan) and imaging cores comparable to those at the Riken imaging facilities.
The center collaborates with academic consortia such as the Japan Clinical Oncology Group, industry associations like the Japan Pharmaceutical Manufacturers Association, and regulatory stakeholders including the Pharmaceuticals and Medical Devices Agency. International partnerships involve exchanges with bodies such as the World Health Organization, the International Committee of Medical Journal Editors, and research networks that include institutions like the National Institutes of Health and the London School of Hygiene & Tropical Medicine. It also works with patient advocacy groups and foundations such as the Japan Cancer Society and professional organizations including the Japanese Association for Medical Informatics.
Funding sources comprise professional association allocations from the Japan Medical Association, grants from public agencies such as the Japan Agency for Medical Research and Development, fee-for-service contracts with healthcare institutions, and collaborative research funding from the Japan Science and Technology Agency. The center administers budgets for investigator-initiated trials and industry-sponsored studies financed by corporations represented by the Japan Pharmaceutical Manufacturers Association and occasionally receives philanthropic support from entities like the Japan Foundation and foundations linked to university hospitals.
The center has supported multicenter trials in cardiovascular disease involving groups such as the Japanese Circulation Society and oncology trials coordinated with the Japan Clinical Oncology Group, contributing to guideline updates cited by organizations like the Japanese Society of Hypertension and the Japanese Society of Gastroenterology. Its capacity-building programs have influenced investigator-initiated research at institutions including Keio University Hospital, Nihon University Hospital, and Chiba University Hospital, and its data management practices have been benchmarked against systems used by the European Medicines Agency and the United States Food and Drug Administration. Notable collaborative studies addressed infectious disease preparedness with the National Institute of Infectious Diseases (Japan) and device trials aligned with standards from the International Organization for Standardization.
Category:Medical research institutes in Japan Category:Clinical trial organizations